Company Description
EntreMed is cancer's new enemy. The company develops drugs that inhibit angiogenesis, or the growth of new blood vessels. One of its lead product...
Key EntreMed Financials
| Company Type | Public - NASDAQ (GM): ENMD Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $7.4 |
| 2005 Employees | 41 |
More EntreMed Financials (10 pages)
Competition
Competitive Landscape for Pharmaceutical Manufacture and Sale
The industry is marked by rapid advances in scientific knowledge that produce ever-more effective medicines. Profitability is determined mainly by the ability to discover new drugs. The industry is...
Read more about EntreMed's competition across multiple industries
Top EntreMed Competitors
Sponsored Links
The Business Directory
EntreMed Executives
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | Michael M. Tarnow | Network | E-mail |
| President, CEO, and Director | James S. (Jim) Burns | Network | E-mail |
| CFO | Dane R. Saglio | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Sponsored Opportunity
